HUMAN DNA SEQUENCE ENCODING A KIDNEY ATP-DEPENDENT POTASSIUM CHANNEL

Abstract: The present invention comprises human DNA compositions encoding proteins that confer potassium channel activity to membranes or recipient cell lines. The DNA compositions include structural genes coding for the potassium channel proteins, expression and replication plasmids or vectors containing the structural genes and host cells expressing those genes. Methods of screening compounds for potassium channel modulating activity are also described.

Description: HUMAN DNA SEQUENCE ENCODING A KIDNEY ATP-DEPENDENT POTASSIUM CHANNEL BACKGROUND OF THE INVENTION 1. Field of the Invention. The present invention comprises human DNA compositions encoding proteins that confer potassium channel activity to membranes or recipient cell lines. The DNA compositions include structural genes coding for the potassium channel proteins, expression and replication plasmids or vectors containing the structural genes and host cells expressing those genes. Methods of screening compounds for potassium channel modulating activity are also described. 2. Description of the Related Art. Ho, K., et. al. "Cloning and expression of an inwardly rectifying ATP-regulated potassium channel." Nature (4 March 1993) Vol. 362 pp. 31-38. Describes the gene that encodes an ATP-regulated potassium channel protein from the inner stripe of outer medulla of rat kidneys. Chandy, K., et. al., WO 92/02634, PCT/US91/05168, published 20 February 1992. Describes the gene product known as MK3, a voltage dependent, type n potassium channel protein in T lymphocytes. Harpold, M., et. al., WO92/02639, PCT/US91/05625, published 20 February 1992. Transcription assays that identify compounds that modulate the activity of cell surface proteins. Cells that contains DNA that encode reporter genes, transcriptional control elements and heterologous cell surface proteins that may be potassium ion channels. Luzdunski, M., "Potassium Channels: Structure-Function Relationships, Diversity, and Pharmacology," Cardiovascular Drugs and Therapy, (1992) Vol. 6, pp. 312-319. General description and information concerning potassium channels. 3. Background. Ionic channels of cell membranes are the basic sites where ionic fluxes take place. The modern era of the study of drug-channel interactions began when voltage clamp techniques were used to demonstrate the block of Sodium, (Na + ), and potassium, (K*), channels of squid axons caused by procaine and cocaine. Narahashi, Ann Neurology (1984); 16(suppl): S39-S51. This invention concerns potassium channels. Pharmacological and biophysical studies have revealed multiple subtypes for membrane ion channels that form potassium selective pores in the plasma membrane of many mammalian cells. Comparison of the pharmacological and electrophysiological properties of these potassium channels has given rise to an operational definition for grouping the various subtypes based largely on their gating properties. Voltage-gated potassium channels sense changes in membrane potential and pass potassium ions in response to this alteration in the cell membrane potential. Ligand-gated potassium channels are regulated by small molecular weight effectors which include calcium, sodium, ATP or fatty acids (particularly arachidonic acid). Lazdunski, Cardiovascular Drugs and Therapy (1992) Vol. 6 pp. 313-319. Although these channel proteins share the common property that they selectively move potassium ions, their distinct biophysical, biochemical and pharmacological properties suggests that they are different gene products encoded by distinct genes. The ATP-Sensitive, or ATP-gated, potassium channel is an important class of channels that links the bioenergetic situation of the cell to its electrical excitability. The channel is blocked by high intracellular ATP concentrations and it opens when ATP decreases. Lazdunski (1992). Although ATP-gated potassium channels were originally described in cardiac tissue; Noma, A. Nature (1983) Vol. 305 pp. 147-148, they have subsequently been described in pancreatic β-cells; Cook et. al., Nature (1984) Vol. 311 pp. 271-273, vascular smooth muscle; Nelson, M.T. et. al., Am. J. Physiol. (1990) Vol. 259 pp. C3-C18 and in the thick ascending limb of the kidney; Wang, W. et. al. Am. J. Physiol. (1990) Vol. 258, pp. F244-F-253. Molecular cloning studies on potassium channel proteins has yielded some information, but only for members of the voltage-gated family of potassium channels. Various genes encoding these voltage-gated family of potassium channel proteins have been cloned using Drosophila genes derived from both the Shaker, Shaw and Shab loci; Wei, A. et. al., Science (1990) Vol. 248 pp. 599-603. All known attempts to clone members of the ligand-gated family of potassium channel proteins using probes based on the known sequences of voltage-gated potassium channels have been unsuccessful. Taken together with the electrophysiological and pharmacological properties of these potassium channels, these results further confirm that the ATP-gated channel proteins are encoded by genes that are distinct from the genes that encode for voltage-gated potassium channels. These results indicate that there is little or no homology between the genes encoding voltage-sensitive potassium channels and the ATP-gated potassium channels. A cDNA encoding a rat kidney potassium channel has been isolated by expression cloning, using a size-fractionated mRNA from the rat kidney thick ascending limb. When expressed in oocytes, the protein encoded by this gene displays many but not all of the hallmarks of a ATP-gated potassium channel. Ho, K., et. al., Nature, Vol. 362 pp. 31-38 (4 March 1993). This invention describes the first successfully cloned human kidney ATP-gated and related potassium channel genes. Cloning these important genes will allow the production of important channel proteins into systems that will permit the identification, characterization and cloning of potential drug targets. This invention includes the development of a high volume mechanistic screen and it will allow the production of appropriate systems for the production of material for biochemical study. The discovery of the highly selective and potent sodium channel blocking action of tetrodotoxin ignited a widespread interest in using specific chemicals as probes for the study of ionic channels. Narahashi (1984). The present invention provides an important potassium channel that may allow the discovery of other important physiological compounds. SUMMARY OF THE INVENTION This invention comprises the first isolation of functional cDNA clones encoding human potassium ATP-gated channel proteins, and derivatives thereof. This invention describes the following. Isolated DNA molecules encoding a human kidney ATP-gated and related potassium channel having the sequences shown in Figures 1-5 and selected derivatives thereof. Various vectors comprising the DNA molecules of Figures 1-5 and selected derivatives thereof. Various plasmids comprising the DNA molecules of Figures 1-5 and selected derivatives thereof. Vectors and plasmids adapted for expression in a bacterial cell, yeast cell, or a mammalian cell. Use of the bacterial, yeast, or mammalian cell containing the vector or plasmid of Figures 1-5 o selected derivatives thereof, to screen for compounds that modulate human kidney ATP-gated and related potassium channel activity. The invention also comprises an isolated DNA molecule encoding a human kidney potassium channel protein, the isolated protein, and isolated mammalian cells comprising the protein, having the sequences shown in Figures 1, 2, 3, 4, or 5; from the clones named K-8, K- 11 or K-12, or derivatives selected from obvious variations thereof, or having the DNA coding for the N-terminal protein sequences as shown in Table 1; from the clones named K-2, K-6, K- 8, K- 11, or K-26 and having the remaining DNA not shown in Table 1 but as shown in Figures 1-5, or having the DNA coding any of about the first 26 N terminal amino acids, including any deletions, of the protein coded for by the DNA shown in Figures 1-5, or the protein shown in Figure 6 or Table 1, or a DNA molecule 90 percent homologous to any of the above described DNA molecules thereof. Also claimed is a method of using a mammalian cell as described above, to screen for compounds that modulate human kidney potassium channel activity. The method may be comprised of the following steps: a) growing cells expressing a cloned K + channel to confluence, b) equilibrating the cells of a) with a balanced salt solution, c) making baseline measurements of the equilibrated cells, d) adding one test compound or a cocktail of test compounds to the cells and recording changes in membrane potential, e) testing compounds that depolarize cells expressing the K + on wild type or mock transfected controls to establish selectivity, f) selecting the compounds that are shown to selectively block K + . BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. Translation of the open-reading frame encoded by cDNA clone K26. Figure 2. Translation of the open-reading frame encoded by cDNA clone K26-plus. Figure 3. Translation of the open-reading frame encoded by cDNA clone Kll. Figure 4. Translation of the open-reading frame encoded by cDNA clone Kll-plus. Figure 5. Translation of the open-reading frame encoded by cDNA clone K-8. Figure 6. Amino acid sequence alignment of human kidney K-ATP channel proteins. Figures 7A-7F. Whole cell recordings of K- 8, Kll and K26 channels expressed in Xenopus oocytes. Figures 8A-8F. Potassium selectivity of the K-8, Kll and K26 channels expressed in Xenopus oocytes. Figure 9. BaCl 2 -induced depolarization of COS 7 cells that are transiently expressing the K26 K x channel analyzed on the ACAS cytometer. Figure 10. BaCl 2 -induced depolarization of human embryonic kidney (HEK 293) cells that are stably expressing the K26 K x channel analyzed on the ACAS cytometer. Figure 11. BaCl 2 -induced depolarization of COS 7 cells that are transiently expressing the ROMK1 K x channel analyzed on the ACAS cytometer. Figure 12. Glyburide-induced depolarization of COS 7 cells that are stably expressing the ROMK1 K x channel analyzed on the ACAS cytometer. Figures 13A-13C. KCl-dependent depolarization of A10 cells analyzed on FLIPR. DESCRIPTION OF THE PREFERRED EMBODIMENTS This invention relates to the cloning and isolation of human DNAs encoding a functional potassium ATP-gated channel proteins. In one embodiment this invention comprises the first isolation of functional cDNA clones encoding human potassium ATP-gated channel proteins as verified by using Xenopus laevis oocytes as an expression system for studying ion channels. Mammalian and a bacterial cell lines expressing functional human potassium ATP-gated channels at the cell surface are described, as determined by pharmacologic and physiologic methods, thus establishing the first well-defined, cell lines with which to study this particular member of a family of ATP-gated channel proteins. In another embodiment those human potassium ATP-gated channels are shown operating in a high volumn screen. Definitions. This document uses abbreviations and terms that should be well known to those skilled in the art. Some terms are more fully described in the sections below. I. ISOLATION OF A FUNCTIONAL HUMAN POTASSIUM CHANNEL DNA CLONE. 1. Isolation of rat kidney cDNA PvuII/BamHI fragment. A rat kidney ATP-potassium channel cDNA termed ROM-Kl incorporated into the plasmid pSPORT is obtained using the procedures described in Ho, K., et. al. "Cloning and expression of an inwardly rectifying ATP- regulated potassium channel." Nature, Vol. 362 pp. 31-38 (4 March 1993), incorporated by reference. This rat kidney ATP-potassium channel cDNA from the plasmid pSPORT is digeste to completion with the restriction endonucleases PvuII and BamHI. The resulting 1.3 kilobase insert DNA containing the entire open-reading frame of ROM-Kl is purified by preparative agarose gel electrophoresis. 2. Radiolabeling of rat fragment. The isolated rat kidney cDNA PvuII BamHI fragmen x γx is radiolabeled using α- P-dATP and random hexamers in the presence of the Klenow fragmen of DNA polymerase I. 3. Isolation of recombinant bacteriophage containing human K-channel cDNAs. A human kidney cDNA library in the bacteriophage vector lambda gtlO is titered on E. coli C600 hfl " and 400,000 independent recombinants are plated on agar plates. Replicate lifts of the agar plates are prepared on nylon membranes and the denatured phage DNA immobilized on the filters by baking. The replicate nylon lifts are prehybridized in buffer to block non-specific binding sites and then hybridized with the J P random -prime labeled PvuII/BamHI fragment of ROM-Kl. The filters are then washed with 0.3 M NaCl/0.1% SDS at 65 °C. The coordinates of radioactivity on the filters are determined by autoradiography at -70°C with intensifying screens. Replicate positive bacteriophage are isolated from the agar plates and cloned by dilution plating and rescreening as described in the Nature article by Ho, above. 4. Preparation of bacteriophage DNA from the clonal phage stocks. Clonal bacteriophage stocks of the hybridization-positive clones, from step 3, above, are used to prepare bacteriophage DNA by infection of E. coli followed by DNA isolation. E. coli cultures are infected with clonal phage and bacteriophage DNA isolated from the infected culture using a combination of polyethylene glycol precipitation of the bacteriophage particles followed by destruction of the bacteriophage protein coat. Bacteriophage DNAs prepared in this manner were digested with EcoRI to produce the cDNA inserts. The size of the liberated insert cDNAs is determined by size fractionation on agarose gels. The fractionated cDNAs are then transferred to a nylon membrane by capillary action and homologous sequences are detected by hybridization to the 32 P-PvuII/BamHI fragment of ROM-Kl and autoradiography as described above. 5. Sequencing of selected bacteriophage DNAs. Bacteriophage DNAs prepared from clones with distinct EcoRI restriction patterns are selected and then sequenced by cycle sequencing dideoxy-chain termination reactions. The dideoxy chain termination method may utilize the SEQUENASE (™) methods and products, available from United States Biochemicals, Cleveland, OH. This is followed by denaturing gel separation of the reaction products, autoradiographic detection of the fractionated DNA bands and manual reading of the gels. 6. Cloning of alternate human K-ATP channel DNAs. The DNA sequence analysis revealed a common core-exon, shared by all of the cDNAs, flanked by alternate 5' sequences. These alternate 5' sequences were further characterized by mapping the transcriptional start-sites for each transcript using a combination of reverse transcriptase/polymerase chain reaction (RT/PCR) amplification and 5' rapid amplification of cDNA ends (RACE) analysis. A synthetic oligonucleotide primer complementary to the shared core exon sequence (HROM 4) was used to reverse transcribe human kidney total RNA using the MMLV reverse transcriptase. The cDNA products were then PCR amplified using either an anchor primer (5' RACE) or a primer specific for the 5' untranslated sequence of the K26 cDNA (HROM-10). This led to the isolation of five distinct cDNAs referred to as: K-8, KI 1, KI 1 + , K26 and K26 + The PCR products were subcloned into plasmid vectors and completely sequenced on both strands as described above. The complete sequences of the K-8, Kll, Kll + , K26, and K26 + cDNAs was assigned using a combination of the bacteriophage cDNA sequences and the sequences of both the RT-PCR and 5' RACE products (Figures 1-5). 7. Selection of the clones and selected derivates of the clones. The DNA sequence of clone K26 contains a single open-reading frame that encodes a 389 amino acid residue protein that displays close sequence identity to the rat kidney ROM-Kl potassium channel with one important difference. The actual amino acid residues found in the N-terminal domain, the first 26 amino acids, and espically the first 10 amino acids, show suprising and unexpected differences from what one would ordinarily predict from an analysis of the rat sequence. The N-terminal amino acid residues, which are present in the intracellular space prior to protein's insertion into the plasma membrane, show a greater than expected divergence from the rat sequence, greater than one would expect given the high homology found in species homologs of the same and similar channel proteins. Note that the K-8 cDNA encodes a human species homolog that is the same length as the rat kidney ROM-Kl channel. When comparing ROM-Kl with K-8, there are important amino acid differences, and the corresponding DNA, is different, yet both the rat and the human have a similar distinct amino acid terminus. Significantly, the Kll, K-ll + , K26 K26 + , and two other K + channel proteins, we call K2 and K-6, have different lengths as well as types of amino acids in this important region. The differences were unexpected, given only the rat sequence. The different human amino acid terminals are shown in Table 1, below: TABLE 1 Kll (deletion)-MFKHLR K2 MCFQ-IRVLTES-MFKHLR K26 MPTVYLCSEQ-IRVLTES-MFKLHR.... K-8 MNASSRNVFDTL-IRVLTES-MFKLHR K-6 MVSELSIPSIPTGVAGLSK-IRVLTES-MFKLHR Thus K2 has 8 fewer sequences than ROM-Kl, while K-6 has 7 sequences more than ROM-Kl. These initial 26 or so N-terminal amino acids are the most important variable region of the protein, the remaining protion of the protein being highly homologous. Investigations show that differences in this N-terminal region may can result in functional differences in the protein. The rat ROM-Kl, and the K8 disclosed here, show little or no inhibition to ATP. The endogenous K + channel is inhibited by ATP, therefore; it is likely that one of the other variants would show inhibition to ATP. It appears that Kll is the most abundant protein in the thick ascending limb of the kidney. In the kidney the functional K + channel is inhibited by ATP, therefore it would be logical to test the protein variants for inhibition by ATP and to use proteins that would are inhibited by ATP to screen for K + blocking agents. Other functional differences may be associated with the other N-terminal sequences. All of these human protein sequences, the DNA that codes for them, obvious variants thereof, homologous sequences thereof, allowing for conservative substitutions but expecting at least 90 percent homology are included as the invention described herein. The first 26 or so N- terminal sequences, or their absence or deletions, are very important but it is also observed that conservative substitutions are to be expected anywhere in the sequence and all are included here. II. PREPARATION OF SUITABLE VECTORS INCORPORATING HUMAN POTASSIUM CHANNEL DNA. 1. The pGEM7 vector. a. Preparation of clone coding sequence. The open-reading frames of the K-8, Kll and K26 clones are obtained by restriction endonuclease digestion of the lambda DNAs with KpnI/AccI, XhoI/AccI or Muni, respectively. The DNA fragments are purified by preparative agarose gel electrophoresis. b. Introduction of the clones into a plasmid vectors. The K-8, Kll and K26 cDNA fragments were subcloned into the multiple cloning site of either pSP64-poly A (K-8 and Kll) or pGEM7 (K26) to yield K-8/pSP64, Kll/pSP64 or pGEM7/K26, respectively. 2. The PSVL/K26 vector. a. The pGEM7/K26 plasmid is double-digested with the restriction endonucleases Xhol and BamHI and the resulting fragment is purified by preparative agarose gel electrophoresis. b. The isolated XhoI/BamHI fragment of K26 is subcloned into the transient expression vector pSVL to yield expression plasmid pSVL/K26. 3. The pCEP4 vector. a. The XhoI/BamHI fragment containing the entire coding sequence of K26 is subcloned into the expression vector pCEP4 to yield the expression vector pCEP/K26. 4. The pMEP vector. a. The XhoI/BamHI fragment containing the entire coding sequence of K26 is subcloned into the expression vector pMEP to yield the expression vector pMEP/K26. 5. The pMAL2c K26 vector. a. The entire coding sequence of K26 is adapted for expression using the polymerase chain reaction (PCR) using primers containing the appropriate restriction endonuclease recognition sites. b. The engineered PvuII/BamHI PCR fragment is subcloned into the bacterial expression vector pMAL2c. c. The integrity of the PCR product is verified by DNA sequencing using the dideoxy-chain termination method. 6. The pYESI vector. a. The entire coding sequence of K26 is adapted for expression using the polymerase chain reaction (PCR) using primers containing the appropriate restriction endonuclease recognition sites (Not I). b. The engineered NOT I PCR fragment is subcloned into the bacterial expression vector pYESI. c. The integrity of the PCR product is verified by DNA sequencing using the dideoxy-chain termination method. III. EXPRESSION OF THE PROTEIN ENCODED BY THE HUMAN POTASSIUM CHANNEL DNA CLONE. 1. Transient expression of K26 clone in COS 7 cells. a. The pSVL/K26 expression plasmid is used to transfect COS 7 cells using the cationic liposome DOTAP. This cationic liposome is available from Boehringer Mannheim, Indianapolis, Indiana. Functional expression is determined by transcript analysis and functional expression is monitored optically by measuring the effect of Ba 2+ on the resting membrane potential of the transfected cells. See Experimental Details, below. 2. Transient expression of K26 clone in oocytes a. Oocyte expression of K-8, KI 1 and K26 clone. i. The pSP64poly A system in Oocytes. 1. The pSP64poly A vector is digested to completion with EcoRI and the product filled-in using Klenow polymerase. The blunt-end product of the fill-in reaction is linkered with Not I linkers and the Not I sites generated by digestion with Not I. 2. The K-8, KI 1 and K26 pSP64poly A plasmid DNAs are linearized by digestion with Not I and purified by preparative gel electrophoresis. 3. Sense cRNA is synthesized off of the BamHI-digested pGEM7/K26 template using SP6 RNA polymerase and 5' capped in the same reaction. 4. Capped cRNA is microinjected into Xenopus oocytes and allowed to express for 72 hours. 5. Potassium channel activity is monitored 72 hours after microinjection by electrophysiological measurements in both the whole cell and detached patch recording modes. See Experimental Details, below. 3. Stable expression of the K26 DNA clone in mammalian cells. a. Chinese hamster ovary (CHO), African Green Monkey Kidney Cells (COS), human embryonic kidney and mouse L-cell expression of K26. i. The pCEP/K26 and pMEP/K26 vector expression systems. 1. The pMEP/K26 and pCEP/K26 expression plasmid are used to transfect Chinese hamster ovary, COS, human embryonic kidney and mouse L-cells using the cationic liposome DOTAP. 2. Stable transfectants are selected by culturing of the cells in the presence of Hygromycin B. Stable clonal cell lines are subcloned several times to insure clonal lineage. The expression of K26 in the transfected cells is determined by analyzing for K26 transcripts (Northern blot analysis and RT-PCR) and using a functional assay. The latter is performed by optically measuring changes in membrane potential using the reporter dye DiBAC after the addition of Ba . The expression of K26 is also determined by electrophysiological procedures. See Experimental Details, below. 4. Stable expression of the K26 DNA clone in bacterial cells, a. The pMAL2c/K26 system. i. Induction of expression of the pMAL2c/K26 plasmid containing DH 5α is induced by addition of IPTG to exponentially growing cultures. ii. Expression of the desired protein product is verified by SDS-PAGE analysis of bacterial cells isolated from the induced cultures. IV. BIOASSAYS USING EXPRESSION SYSTEMS BASED ON THE PROTEIN ENDCODED BY THE HUMAN POTASSIUM CHANNEL DNA CLONE. This section describes methods and procedures for using the bacterial cells, yeast cells and or mammalian cells expressing the human kidney ATP-gated and related potassium channel to screen for compounds that modulate human kidney ATP-potassium channel activity. Mammalian cells that are stably transfected with K26 are grown in multiwell tissue culture dishes. The tissue culture dish of choice is one that contains 96 wells. Other tissue culture dishes could also be used. The membrane potential of the mammalian cells expressing K26 is optically measured using a voltage-sensitive fluorescent dye. The dye of choice is bis(l,3-dibutylbarbituric acid)trimethine oxonol (DiBAC 4 (3). Other voltage sensitive dyes could also be used. Changes in membrane potential are detected by measuring changes in cellular fluorescence against a high background of noncellular fluorescence. The cell associated fluorescence is measured, not just the total well fluorescence. A better system for measuring changes in membrane potential is to use a 96 well plate reader that can measure changes in cellular fluorescence against a high background of noncellular fluorescence for all 96 wells at once. FLIPR a laser system manufactured and available from NovelTech, Ann Arbor, Michigan is one such system. The screen consists of adding agents to cells that express K26. Agents that block K26 cause the cells to depolarize. Agents that activate K26 cause the cells to hyperpolarize. Specificity is determined in several ways. The first test of specificity is to determine if agents of interest modulate the membrane potential of mock transfected cells. These cells contain the vector that K26 is cloned into but do not express the K26 gene product. Other tests of specificity include determining if agents of interest modulate the activity of other K + channels. The invention should be readily appreciated and understood by those skilled in the art from the descriptions above. The following Experimental Details are supplied to provide details of the best mode of the invention and to illustrate the completed invention more fully. They should not be considered limitations on the invention. EXPERIMENTAL DETAILS I. ISOLATION OF A FUNCTIONAL HUMAN POTASSIUM CHANNEL DNA CLONE. 1. Isolation of rat kidney cDNA PvuII/BamHI fragment. A rat kidney ATP-potassium channel cDNA termed ROM-Kl is obtained using the procedures described in Ho, K., et. al. "Cloning and expression of an inwardly rectifying ATP- regulated potassium channel." Nature, Vol. 362 pp. 31-38 (4 March 1993). The ROM-Kl cDNA in the plasmid vector pSPORT was passaged in E. coli strain DH 5α under ampicillin selection (Maniatis, et al., Molecular Cloning, Cold Spring Harbor Laboratory, 1982). Purified plasmid DNA was double-digested with the restriction endonucleases PvuII and BamHI and the resulting 1.3 kilobase fragment containing the entire open-reading frame of ROM-Kl was purified by preparative agarose gel electrophoresis followed by electroelution of the isolated fragment. 2. Radiolabeling of rat fragment. The isolated rat kidney cDNA PvuII/BamHI, 1.3 kilobase restriction fragment was radiolabeled using α- 32 P-dATP and random hexamers in the presence of the Klenow fragment of DNA polymerase I (A.P. Feinberg and B. Vogelstein, Anal. Biochem. 137, 266 (1984)). 3. Preparation of human positive bacteriophage. A human kidney cDNA library in the bacteriophage vector lambda gtlO, purchased from Clonetech, Palo Alto, California is titered on E. coli C600 hfl " and 400,000 independent recombinants are plated on agar plates. Replicate lifts of the agar plates are prepared on nylon membranes and the phage DNA immobilized on the filters by baking. The replicate nylon lifts are prehybridized in buffer to block non-specific binding sites and then hybridized with the 32 P- labeled PvuII/BamHI fragment, labeled as described above. The filters are then washed with 0.3 M NaCI/0.1% SDS at 65 °C. The coordinates of radioactivity on the filters is determined by autoradiography at -70°C with intensifying screens. Sixty two replicate positives were identified from the primary screen and each of these replicate positives is cloned by limiting dilution followed by reiterative plating on agar plates and rescreening with the 3 P-labeled ROM-Kl probe and autoradiography as described above. 4. Preparation Bacteriophage DNA from the Clonal phage stocks. Bacteriophage DNA is prepared from the clonal phage stocks of positive clones, from step 3, above, by infection of E. coli followed by DNA isolation. E. coli cultures infected with bacteriophage from clonal stocks are used to prepare bacteriophage DNA by lysis followed by polyethylene glycol precipitation and destruction of the bacteriophage protein coat (Maniatis, et al., Molecular Cloning, Cold Spring Harbor, 1982). Purified bacteriophage lambda DNAs were digested with EcoRI to produce fractionated cDNAs. The size of the liberated insert cDNAs is determined by size fractionation on agarose gels. The fractionated cDNAs are then transferred to a nylon membrane by capillary action and homologous sequences are detected by hybridization to the 32 P-PvuII/BamHI fragment and autoradiography as described above (Southern, E. Mol. Biol. 98, 503 (1975)). Homologous DNA sequences are detected by hybridization with 32 P-labeled DNA fragments derived from various portions of the ROM-Kl coding sequence followed by low stringency washes as described above. Phage DNAs displaying unique hybridization patterns were then subjected to DNA sequence analysis. 5. Sequencing of selected bacteriophage DNAs. Bacteriophage DNAs from clones with distinct EcoRI restriction patterns are selected and then the DNA sequence of each bacteriophage is determined directly from the bacteriophage DNAs using cycle sequencing dideoxy-chain termination reactions. (AmpliTaq kit, Perkin Elmer-Cetus, Norwalk, Connecticut). The reaction products are resolved on 1 meter denaturing polyacrylamide gels followed by autoradiographic detection of the fractionated DNAs. Manual reading of the DNA sequence is then performed. 6. Mapping of the human kidney transcript 5' ends Sequence analysis of the bacteriophage cDNAs isolated from the human kidney library revealed a common core exon fused to variable 5' sequences. The transcripts that give rise to these cDNAs were further analyzed by reverse transcriptase cDNA synthesis coupled to the polymerase chain reaction amplification of the K-channel transcripts (RT-PCR). First strand cDNA synthesis was primed using oligo dT and MMLV reverse transcriptase (Bethesda Research Laboratories, Gaitherburg, Maryland) on a human kidney total RNA template. A portion of the first strand cDNA product was PCR amplified using a common 3' oligonucleotide primer that is specific for the core-exon (HROM-4) combined with a 5' oligonucleotide primer that is specific for either the K-8 or KI 1/K26 cDNAs. These products of the PCR amplification reactions were fractionated according to size on an agarose gel and recovered by electroelution. Each individual fragment was blunt-ended using Klenow fragment of DNA polymerase I, phosphorylated using T4 polynucleotide kinase and subcloned into Smal digested pUC19. The sequence of each subcloned PCR product was determined by the dideoxy chain termination method using SEQUENASE ™ (United States Biochemicals, Cleveland, Ohio). Composite cDNA sequences were constructed using a combination of the cDNA sequences and the sequences obtained from the RT-PCR products and are shown in Figure 2. Our analysis revealed 5 distinct transcripts in the human kidney. 7. Selection of the clone. Translation of the open reading frames encoded by the 5 distinct transcripts isolated from human kidney RNA showed that they had the potential to encode 3 distinct amino terminal variants of human the kidney K ATp channel protein. Each transcript encoded a protein that had all of the hallmarics of a K ATp channel protein including the presence of two predicted membrane spanning domains, a region that showed remarkable homology to the Shaker K- channel H5 domain and a single predicted ATP-binding site. Clone K-8 contained a 1173 base- pair open reading frame that encoded a 391 amino acid protein that was > 92% identical to rat kidney ROM-Kl. Clone K26 contained a single open-reading frame (1167 base-pair) that encoded a 389 amino acid residue protein that was identical to K-8 except that the amino terminus (10 amino acid residues) was completely distinct. Finally, clones Kll, Kll + and K26 + all encoded the same 372 residue channel protein, that was an amino terminal truncated version of either K-8 or K26 that is lacking either the amino terminal 19 or 17 residues from K- 8 and K26, respectively. Each DNA sequence was engineered for expression in the vectors for mammalian cell expression (pCEP and pMEP), for oocyte expression (pSP64-poly A), for bacterial expression (pMAL2c) or yeast expression (pYES) and these constructs used to express the various human kidney K ATp channels in the appropriate host. 8. Clone purification. The K26 lambda DNA is digested with the restriction endonuclease Muni and the 1.3 kilobase fragment is purified by preparative agarose gel electrophoresis. II. PREPARATION OF SUITABLE VECTORS INCORPORATING HUMAN POTASSIUM CHANNEL DNA. 1. The pGEM7 vector. The 1.3 kilobase Muni restriction fragment is subcloned into the EcoRI site of the plasmid vector pGEM7. cRNA capping. The pGEM7/K26 plasmid is linearized with BamHI. The linearized plasmid is then transcribed and capped with 7MeGppp5'G using T7 RNA polymerase. 2. The PSVL/K26 vector. The pGEM7/K26 plasmid is double digested with Xhol and BamHI and the resulting fragment subcloned into pSVL to yield pSVL/K26. 3. The pCEP4 vector. The XhoI/BamHI fragment of K26 is subcloned into the plasmid vector pCEP to yield pCEP/K26. 4. The pMEP vector. The XhoI/BamHI fragment of K26 is subcloned into the plasmid vector pMEP to yield pMEP/K26. III. EXPRESSION OF THE PROTEIN ENDCODED BY THE HUMAN POTASSIUM CHANNEL DNA CLONE. 1. Transient expression of K26 clone in COS 7 cells. The plasmid pGEM7/K26 is digested to completion with the restriction endonucleases Xhol and BamHI and the 1.3 kb fragment containing the K26 coding sequence is isolated by preparative agarose gel electrophoresis. This fragment is ligated to the plasmid vector pSVL and the ligation products used to transform competent E. coli DH5 α cells. pSVL/K26 expression plasmid DNA is prepared from the appropriate clone and purified pSVL/K26 plasmid DNA is used to transfect COS 7 cells using the cationic liposome DOTAP (Boehringer Mannheim, Indianapolis, Indiana). Channel activity is detected 48-72 hours post transfection. 2. Stable expression of the K26 DNA clone in mammalian cells. a. Chinese hamster ovary (CHO), African Green Monkey Kidney Cells (COS), human embryonic kidney and mouse L-cell expression of K26. i. The pCEP/K26 or the pMEP/K26 expression plasmids are used to transfect COS 7 cells or human embryonic kidney cells (293 cells) using the cationic liposome DOTAP. 20 hour post-transfection, the cells are treated with 0.15 - 0.5 mg/ml hygromycin B to kill non- transfected cells. Individual cell lines are isolated by single cell cloning. 3. Functional Expression of K-8, KI 1 and K26 cRNAs in Xenopus oocytes. We examined the electrophysiological properties of the K-8, KI 1 and K26 polypeptides by expression in Xenopus oocytes. Polyadenylated cRΝAs (45 nl of a 100 ng/ul) were injected into oocytes and allowed to express for 48-72 hr. Forty eight hour post injection with K-8, KI 1 or K26, the oocytes had resting membrane potentials of -90.08 ±1.90mV (n=9), -97.2 ±OmV (n=l) and -88.75 ±0.45mV (n=2) respectively, and these remained relatively unchanged at - 87.89 ±1.57mV (n=7), -93 ±0.79mV (n=7) and -88.4 ±2.11mV (n=4) on day 3. The water injected control oocytes had average resting potentials of about -40 mV. The significantly more negative potential of oocytes injected with ROM-K cRΝAs is due to functional expression of these channels and the values are close to the K equilibrium potential calculated for the estimated K gradient (2 mM extracellular/100 mM intracellular). Currents were recorded by the two microelectrode voltage clamp technique using oocytes expressing K-8, Kl l or K26 cRΝAs and the results are shown in Figures 7A-F. Figures 7 A, 7B and 7C show typical current traces recorded in 50 mM external K + from oocytes injected with K-8, Kll or K26, respectively. In Figures 7D, 7E and 7F the Y axis is cuιτent in micro amperes, the X axis is membrane potential in millivolts. The corresponding I- V relationships are depicted as open circles (o) in Figures 7D, 7E and 7F. In all cases, currents at potentials positive to the holding potential of -20 were directed outward and those at potentials negative to -20 mV were directed inward. The amplitude of the inward currents are consistently greater than that of the outward current, thus creating inward rectification. The current activation time course of these cloned channels are similar, with two distinct phases: a rapid, almost instantaneous phase followed by a slower, time dependent phase. Once activated, the current does not decline or inactivate in either direction. Application of 1 mM Ba 2+ selectively blocks the inward current, in a time and voltage dependent manner that is most prominent on K-8 (Figures 7D, 7E and 7F, filled circles (•)). The Ba 2+ block was reversed following washout (Figures 7D, 7E and 7F, open squares (□)). The lack of effect of Ba 2+ on the outward current may suggest a "knock-off effect of the Ba 2+ from its channel binding site by the competing K + ions that are moving outward. To examine the K + selectivity of the channels, external KC1 concentrations were increased from 5 mM to 100 mM and choline CI was substituted to maintain the osmolarity. The results shown in Figures 8A-8F illustrate the relationship between reversal potential (E rev ) and external K + concentrations for K-8, KI 1 or K26 (Figures 8A, 8B and 8C, respectively). In Figures 8A-8C the Y axis is reversal potential (E rev ) in millivolts and the X axis is Potassium Concentration in milliMolar. The data were fitted to the Νemst relationship and yielded a slope per decade change of K + concentrations of 57.87 mV for K-8, 57.45 mV for Kll and 53.53 mV for K26, all within the theoretical value of the 58 mV for K + selective electrodes at room temperature. The membrane conductance, g k , of the inward rectifying potassium channel increases as [K + ] 0 is raised. The relationship between membrane conductance, g k , and [K + ] 0 is given by g k = C[K + ] 0 Z where C is a proportion factor, [K + ] 0 is external K + concentration in mM and Z, the exponent factor. We measured the slope conductance of these channels in solutions containing (in mM) 5, 10, 25, 50 and 100 KC1 and the results are shown in Figures 8D, 8E and 8F, respectively for K-8, KI 1 and K26. In Figures 8D, 8E and 8F, the Y axis is g/g max , the X axis is [K + ] Q . The relationship of channel conductance with external [K + ] is non-linear, declining at higher [K + ]. The average values of Z for K-8, Kll and K26 are 0.396±0.05 (n=5), 0.383±0.097 (n=5) and 0.488±0.01 (n=4) respectively. These results further support the conclusion that the K + ion permeations through the inward rectifying channels deviate from the independence principle and this means that ion-ion interactions in the channel are taking place. 4. Optical measurement of channel activity in mammalian cells. We also examined the functional expression K26 by both transient and stable transfection of mammalian cell. Initially, functional expression of K26 K + channel expression was determined using a voltage-sensitive dye and an instrument to record changes in cellular fluorescence. The dye of choice is bis(l,3-dibutylbarbituric acic)trimenthine oxonol) DiBAC 4 (3). Other voltage sensitive dyes could also be used. To optically measure changes in membrane potential, cells were subcultured onto coverglass chambers and grown to confluence. Immediately prior to analysis, cells were washed several times with Earle's balanced salt solutions that was buffered to pH 7.4 with 20 mM Hepes (EBSS-H) and then placed in the same buffer containing 5 μM Dibac 4 (3). Fluorescent imaging of membrane potential was carried out after the cells were equilibrated with 5 μM Dibac 4 (3) for 15 min at 37 °C and then placed in a 35 °C temperature-regulated mini-incubator that was mounted on the stage of a laser-based imaging cytometer (ACAS 570, Meridian Instruments). The ACAS 570 was configured to excite the cells at 488 nm using an argon ion laser. The fluorescent emission was collected at 535 nm using a 495 nm LP dichroic mirror and a 10 nm band pass filter centered at 525 nm. In all cases, data was collected every 60 seconds for at least 25 minutes using the Kinetic program within the ACAS software. Changes in fluorescence were computed using a logistical model developed at Upjohn Laboratories. Control experiments established that the addition of solvents such as dimethylsulfoxide and ethanol had no effect at concentration up to 0.8% (v/v). Previous studies by Epps et. al. (Chemistry and Physics of Lipids, in press 1994) and Holevinsky et. al. (J. Membrane Biology, in press 1994) established that there is a linear relation between changes in fluorescence and changes in membrane potential indicating that the optical membrane potential assay is quantitative. Other imaging instruments and/or spectrofluorometers could also be used to optically measure changes in membrane potential. In the case of K26, the data in Section III (3), indicated that the heterologously expressed K26 K + channel has a very high open probability. These data predicted that if K + channel blocker is added to cells that express the K26 K + channel, then the membrane potential of the cells expressing the channel should be depolarized. The data in Figure 9 confirmed this prediction. In Figures 9-12B the Y axis, labeled RF, is Relative Fluorescence and the X axis, labeled T, is Time, in minutes (min). When compounds, such as glyburide or glipizide (e.g. Figures 12A and 12B) are added to the cell solutions, the additions are always made at Time equals seven (7) minutes. The data in Figure 9 establish that when 1 mM Ba ++ is added to COS 7 cells (arrow; Figure 9) that are transiently expressing the K26 K + channel (open triangles; Figure 9), the membrane potential is depolarized. Previous studies by Ho et. al. established that Ba ++ blocks the K26 class of inwardedly rectifying K + channels. When 1 mM BaCl 2 is added to wild type COS 7 cells (arrow; Figure 9), there is little effect on the membrane potential (solid circles; Figure 9). These data indicate that wild type COS 7 cells do not express Ba ++ -sensitive ion channels, thus making them good recipients cells for K + channel expression studies. The K26 K + channel can also be stably expressed in mammalian cells. As indicated by the data in Figure 10 when 3 mM BaCl 2 (arrow; Figure 10) was added to HEK 293 cells that were transfected with K26 cDNA (open triangles; Figure 10) the membrane potential was depolarized. In this experiment, the HEK 293 cells expressing K26 were passaged 16 times, indicating that K26 stably expressed. When 3 mM BaCl 2 (arrow; Figure 10) to wild type HEK 293 cells (solid circles; Figure 10) there was no effect on the membrane potential. Electrophysiological studies confirm the conclusions from the optical membrane potential assay. Taken together, these data indicate that the optical membrane potential assay can be used to find new chemical entities that block K26 K + channel activity when this channel is expressed in mammalian cells. 5. Development of a high volume screen for agents that block K26 K + channel activity. We have developed a high volume screen to find new chemical entities that block the K26 K + channel activity. The key features of the screen are to use the optical membrane potential assay described in Section III (4), to find new chemical entities that depolarizes COS 7 or HEK 293 cells that express K26 or related potassium channel proteins. Note that it might be that the BEST K + channel protein to use in a screen would be the KI 1 protein because of its sensitivity to ATP, see Experimental Details, Section I, Part 7. Selection of the clone and selected derivatives. It is anticipated that all of the disclosed clones and obvious variants of the initial 30 or so amino acids or so would be used to screen for K + channel blockers. To be selective, the agents that depolarize cells expressing the K26 (or Kl l etc.) K + channel should have little to no effect on wild type cells or mock transfected control cells. Conversely, if a new chemical entity is found that depolarizes both COS 7 and HEK 293 cells whether or not they express the K26 (or KI 1 etc.) K + channel, then it will be concluded that this new chemical entity has no selectivity for K26 (or KI 1 etc.). Thus, selectivity of K + blockade will be judged by a pairwise comparison of the same cell type that is either expressing or not expressing K26 (or KI 1 etc.). In this way, a nonspecific measure of a change in membrane potential can be used to find new chemical entities that selectively block K26 (or KI 1 etc.) K + activity. Operation of the screen. The data in Figure 11 shows that when the ROMKl K + channel is transiently expressed in COS cells (solid circles; Figure 11) the addition of 2 mM BaCl 2 (arrow; Figure 11) causes the membrane potential to depolarize. The addition of 2 mM BaCl 2 (arrow; Figure 11) has little effect on wild type COS 7 cells (open circles; Figure 11). These data indicate that both the ROMKl and the K26 K + channel are sensitive to Ba ++ . Furthermore, we have found that the addition of 100 μM glyburide (arrow; Figure 12A), a sulfonylurea that is known to block K ATp channels, causes COS 7 cells that are stably expressing the ROMKl K + (open triangles, Figure 12A) to be depolarized. The addition of 10 μM glyburide to wild type COS 7 (solid circles; Figure 12A) produced a hyperpolarization. These data indicate that glyburide is blocking the ROMKl channel expressed in COS 7 cells. To determine pharmacological selectivity we also examined the effect of other sulfonylureas that are closely related to glyburide. The data in Figure 12B indicate that the addition of 100 μM glipizide (arrow; Figure 12B) had no effect on the membrane potential of COS 7 cells expressing the ROMKl K + channel (solid circles; Figure 12B). In addition, 100 μM glipizide (arrow; Figure 12B) had no effect on the membrane potential of wild type COS 7 cells (open triangle: Figure 12B). Taken together these data illustrate that the optical membrane potential assay can find compounds in a chemical series that specifically interact with heterologously expressed K + channels. To rapidly screen for new chemical entities that selectivity block K26 or (KI 1) K + activity we utilized a newly developed 96 well fluorescent imaging plate reader called FLIPR (NovelTech, Ann Arbor, MI). This instrument can simultaneously, optically, measure changes in the membrane potential of cells in each well of a 96 well microtest plate. See Figure 13A. When a solvent control is added to A10 smooth muscle cells (min 7; Figure 13A) there is little effect on the membrane potential (all lines in Figure 13A). (A10 smooth muscle cells are available from the American Type Tissue Collection, ATCC number CRL-1476.) The Y axis of Figures 13A, 13B, and 13C, not labeled in the Figure, shows the Percent of Maximal Response, the X axis shows the Time (T) in minutes (min). When 3 mM KC1 is added to A10 smooth muscle cells (min 7; Figure 13B) that are grown in 5 mM KC1, there is a small but statistically significant change in the membrane potential (all lines in Figure 13B). When 30 mM KC1 is added to A10 smooth muscle cells (min 7; Figure 13C) there is large change in the membrane potential (all lines Figure 13C). The data clearly shows that the optical membrane potential assay can be used to detect agents that alter the membrane potential of cells. The optimal screening strategy is to use the optical membrane potential assay and FLDPR to find new chemical entities that block the activity of the K26 (or KI 1) K + channel expressed in COS and HEK 293. In summary, the screen may operate according to the following steps: 1) Cells expressing the cloned K26 (or Kll) K + channel are grown to confluence in a 96 well microtest plate. 2) Cells are equilibrated with 5 μM DiBAC (3) in Earle's balanced salt solution containing 20 mM HEPES. 3) Baseline measurements of each well are recorded. 4) One test compound or a cocktail of test compoimds are added to each well and changes in membrane potential are recorded. 5) Compounds that depolarize cells expressing K26 are then tested on wild type or mock transfected controls to establish selectivity. 6) Compounds that are shown to selectively block K26 will be tested for diuretic efficacy in animal models. Over 5000 compounds per month can be analyzed with this screening protocol. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: The Upjohn Company, Mike J. Bienkowski, Vlnce E. Groppi, Jr. (ii) TITLE OF INVENTION: HUMAN DNA SEQUENCES ENCODING A KIDNEY ATP-DEPENDENT POTASSIUM CHANNEL (iii) NUMBER OF SEQUENCES: 5 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Upjohn Corporate Intellectual Property Law (1920-32-1) (B) STREET: 301 Henrietta Street (C) CITY: Kalamazoo (D) STATE: Michigan (E) COUNTRY: U.S.A. (F) ZIP: 49001 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 ( i) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/021,616 (B) FILING DATE: 19-FEB-1993 ( iii) ATTORNEY/AGENT INFORMATION: (A) NAME: Wootton, Thomas A. (B) REGISTRATION NUMBER: 35,004 (C) REFERENCE/DOCKET NUMBER: 4750.1CP (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 616 385-7914 (B) TELEFAX: 616 385-6897 (C) TELEX: 224 401 UPJOHN (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1740 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: CDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (vii) IMMEDIATE SOURCE: (A) LIBRARY: Human Kidney cDNA (B) CLONE: K26 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CGGGGGCCTC GGGTACCCTC ACCCAGCATA TCCAAACTCT TGCATCAAAG GTGCAGGGAC 60 TTGCTCACAT CGAGAATCTG GTTGCTTTCT TGGAGACCAA GAAAATGAGT TTTTGTTTCT 120 ACATTTACTC CAGCAATCCA TGAGGACTTT ATAGGAATTT TGCACCATTC TGAATGGATA 180 CATTTGGATT TCTCAACATT TGTTCAGCTT CCTAATGACT GTTGTGACAA TTGCTCTATA 240 CCAGTGAATG CCAACTGTTT ATCTCTGCTC TGAACAGATC AGGGTGTTGA CAGAAAGTAT 300 GTTCAAACAT CTTCGGAAAT GGGTCGTCAC TCGCTTTTTT GGGCATTCTC GGCAAAGAGC 360 AAGGCTAGTC TCCAAAGATG GAAGGTGCAA CATAGAATTT GGCAATGTGG AGGCACAGTC 420 AAGGTTTATA TTCTTTGTGG ACATCTGGAC AACGGTACTT GACCTCAAGT GGAGATACAA 480 AATGACCATT TTCATCACAG CCTTCTTGGG GAGTTGGTTT TTCTTTGGTC TCCTGTGGTA 540 TGCAGTAGCG TACATTCACA AAGACCTCCC GGAATTCCAT CCTTCTGCCA ATCACACTCC 600 CTGTGTGGAG AATATTAATG GCTTGACCTC AGCTTTTCTG TTTTCTCTGG AGACTCAAGT 660 GACCATTGGA TATGGATTCA GGTGTGTGAC AGAACAGTGT GCCACTGCCA TTTTTCTGCT 720 TATCTTTCAG TCTATACTTG GAGTTATAAT CAATTCTTTC ATGTGTGGGG CCATCTTAGC 780 CAAGATCTCC AGGCCCAAAA AACGAGCCAA GACCATTACG TTCAGCAAGA ACGCAGTGAT 840 CAGCAAACGG GGAGGGAAGC TTTGCCTCCT AATCCGAGTG GCTAATCTCA GGAAGAGCCT 900 TCTTATTGGC AGTCACATTT ATGGAAAGCT TCTGAAGACC ACAGTCACTC CTGAAGGAGA 960 GACCATTATT TTGGACCAGA TCAATATCAA CTTTGTAGTT GACGCTGGGA ATGAAAATTT 1020 ATTCTTCATC TCCCCATTGA CAATTTACCA TGTCATTGAT CACAACAGCC CTTTCTTCCA 1080 CATGGCAGCG GAGACCCTTC TCCAGCAGGA CTTTGAATTA GTGGTGTTTT TAGATGGCAC 1140 AGTGGAGTCC ACCAGTGCTA CCTGCCAAGT CCGGACATCC TATGTCCCAG AGGAGGTGCT 1200 TTGGGGCTAC CGTTTTGCTC CCATAGTATC CAAGACAAAG GAAGGGAAAT ACCGAGTGGA 1260 TTTCCATAAC TTTAGCAAGA CAGTGGAAGT GGAGACCCCT CACTGTGCCA TGTGCCTTTA 1320 TAATGAGAAA GATGTTAGAG CCAGGATGAA GAGAGGCTAT GACAACCCCA ACTTCATCTT 1 80 GTCAGAAGTC AATGAAACAG ATGACACCAA AATGTAACAG TGGCTTTTCA ACAGGAGTAA 1440 AGAAAGTCTC TAAAGCTCCT AGTACCTAGA AGCATTATGA AGCAGTCAAC AATTTAGGGG 1500 TACGAAAGTA GGATGAGAGC CTTCAAAGTC TACCAGCACA AAGACCCCTG AGCCCCGCAA 1560 TTGTGATCCC ACAAGACATG CATCTCCACA AGGCTACTGT ATTAGAACGT GCAATGCATT 1620 TATATGAAAC TGGTGTATGG AAGACATAGG TGCTCTCTTG AAATCTTAAA TATGATTATT 1680 TGAGCTCATA TAAGGTGGAT TGGAGCAGAT AAAATTACCA AAAGTTTCAT GAACAGGCCG 1740 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1832 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (vii) IMMEDIATE SOURCE: (A) LIBRARY: Human Kidney cDNA (B) CLONE: K26P (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: TGGTTGCTTT CTTGGAGACC AAGAAAATGA GTTTTTGTTT CTACATTTAC TCCAGCAATC 60 CATGAGGACT TTATAGGAAT TTTGCACCAT TCTGAATGGA TACATTTGGA TTTCTCAACA 120 TTTGTTCAGC TTCCTAATGA CTGTTGTGAC AATTGCTCTA TACCAGTGAA TGCCAACTGT 180 TTATCCCTGC TCTGAACAGG TTTCTTCTCT ACTGTGCCTT CATCCCCATC CTGGGCCCTG 240 ACAAAGACAG TGTGACAAGT TCTGAGCCCC ACAGGTGGAA TCCCAAACCA AGCAGCTCTT 300 GCTGGTCACC CCAAGATCTA CTTATACATG AAGTTTTGAA AATCATCTCC TGAACCTCTT 360 CTGACAGAGA TCAGGGTGTT GACAGAAAGT ATGTTCAAAC ATCTTCGGAA ATGGGTCGTC 420 ACTCGCTTTT TTGGGCATTC TCGGCAAAGA GCAAGGCTAG TCTCCAAAGA TGGAAGGTGC 480 AACATAGAAT TTGGCAATGT GGAGGCACAG TCAAGGTTTA TATTCTTTGT GGACATCTGG 540 ACAACGGTAC TTGACCTCAA GTGGAGATAC AAAATGACCA TTTTCATCAC AGCCTTCTTG 600 GGGAGTTGGT TTTTCTTTGG TCTCCTGTGG TATGCAGTAG CGTACATTCA CAAAGACCTC 660 CCGGAATTCC ATCCTTCTGC CAATCACACT CCCTGTGTGG AGAATATTAA TGGCTTGACC 720 TCAGCTTTTC TGTTTTCTCT GGAGACTCAA GTGACCATTG GATATGGATT CAGGTGTGTG 780 ACAGAACAGT GTGCCACTGC CATTTTTCTG CTTATCTTTC AGTCTATACT TGGAGTTATA 840 ATCAATTCTT TCATGTGTGG GGCCATCTTA GCCAAGATCT CCAGGCCCAA AAAACGAGCC 900 AAGACCATTA CGTTCAGCAA GAACGCAGTG ATCAGCAAAC GGGGAGGGAA GCTTTGCCTC 960 CTAATCCGAG TGGCTAATCT CAGGAAGAGC CTTCTTATTG GCAGTCACAT TTATGGAAAG 1020 CTTCTGAAGA CCACAGTCAC TCCTGAAGGA GAGACCATTA TTTTGGACCA GATCAATATC 1080 AACTTTGTAG TTGACGCTGG GAATGAAAAT TTATTCTTCA TCTCCCCATT GACAATTTAC 1140 CATGTCATTG ATCACAACAG CCCTTTCTTC CACATGGCAG CGGAGACCCT TCTCCAGCAG 1200 GACTTTGAAT TAGTGGTGTT TTTAGATGGC ACAGTGGAGT CCACCAGTGC TACCTGCCAA 1260 GTCCGGACAT CCTATGTCCC AGAGGAGGTG CTTTGGGGCT ACCGTTTTGC TCCCATAGTA 1320 TCCAAGACAA AGGAAGGGAA ATACCGAGTG GATTTCCATA ACTTTAGCAA GACAGTGGAA 1380 GTGGAGACCC CTCACTGTGC CATGTGCCTT TATAATGAGA AAGATGTTAG AGCCAGGATG 1440 AAGAGAGGCT ATGACAACCC CAACTTCATC TTGTCAGAAG TCAATGAAAC AGATGACACC 1500 AAAATGTAAC AGTGGCTTTT CAACAGGAGT AAAGAAAGTC TCTAAAGCTC CTAGTACCTA 1560 GAAGCATTAT GAAGCAGTCA ACAATTTAGG GGTACGAAAG TAGGATGAGA GCCTTCAAAG 1620 TCTACCAGCA CAAAGACCCC TGAGCCCCGC AATTGTGATC CCACAAGACA TGCATCTCCA 1680 CAAGGCTACT GTATTAGAAC GTGCAATGCA TTTATATGAA ACTGGTGTAT GGAAGACATA 1740 GGTGCTCTCT TGAAATCTTA AATATGATTA TTTGAGCTCA TATAAGGTGG ATTGGAGCAG 1800 ATAAAATTAC CAAAAGTTTC ATGAACAGGC CG 1832 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1671 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (vii) IMMEDIATE SOURCE: (A) LIBRARY: Human Kidney cDNA (B) CLONE: Kll ( i) SEQUENCE DESCRIPTION: SEQ ID NO:3: CGGGTTGCAT ACAGATGAGT TGGCAGCCGG TCTGAGCTGG CCCACAGACT CATAAAATCA 60 ACAGGGCCTC GGGTACCCTC ACCCAGCATA TCCAAACTCT TGCATCAAAG GTGCAGGGAC 120 TTGCTCACAT CGAGAATCTG GTTGCTTTCT TGGAGACCAA GAAAATGAGT TTTTGTTTCT 180 ACATTTACTC CAGCAATCCA TGAGATCAGG GTGTTGACAG AAAGTATGTT CAAACATCTT 240 CGGAAATGGG TCGTCACTCG CTTTTTTGGG CATTCTCGGC AAAGAGCAAG GCTAGTCTCC 300 AAAGATGGAA GGTGCAACAT AGAATTTGGC AATGTGGAGG CACAGTCAAG GTTTATATTC 360 TTTGTGGACA TCTGGACAAC GGTACTTGAC CTCAAGTGGA GATACAAAAT GACCATTTTC 420 ATCACAGCCT TCTTGGGGAG TTGGTTTTTC TTTGGTCTCC TGTGGTATGC AGTAGCGTAC 480 ATTCACAAAG ACCTCCCGGA ATTCCATCCT TCTGCCAATC ACACTCCCTG TGTGGAGAAT 540 ATTAATGGCT TGACCTCAGC TTTTCTGTTT TCTCTGGAGA CTCAAGTGAC CATTGGATAT 600 GGATTCAGGT GTGTGACAGA ACAGTGTGCC ACTGCCATTT TTCTGCTTAT CTTTCAGTCT 660 ATACTTGGAG TTATAATCAA TTCTTTCATG TGTGGGGCCA TCTTAGCCAA GATCTCCAGG 720 CCCAAAAAAC GTGCCAAGAC CATTACGTTC AGCAAGAACG CAGTGATCAG CAAACGGGGA 780 GGGAAGCTTT GCCTCCTAAT CCGAGTGGCT AATCTCAGGA AGAGCCTTCT TATTGGCAGT 840 CACATTTATG GAAAGCTTCT GAAGACCACA GTCACTCCTG AAGGAGAGAC CATTATTTTG 900 GACCAGATCA ATATCAACTT TGTAGTTGAC GCTGGGAATG AAAATTTATT CTTCATCTCC 960 CCATTGACAA TTTACCATGT CATTGATCAC AACAGCCCTT TCTTCCACAT GGCAGCGGAG 1020 ACCCTTCTCC AGCAGGACTT TGAATTAGTG GTGTTTTTAG ATGGCACAGT GGAGTCCACC 1080 AGTGCTACCT GCCAAGTCCG GACATCCTAT GTCCCAGAGG AGGTGCTTTG GGGCTACCGT 1140 TTTGCTCCCA TAGTATCCAA GACAAAGGAA GGGAAATACC GAGTGGATTT CCATAACTTT 1200 AGCAAGACAG TGGAAGTGGA GACCCCTCAC TGTGCCATGT GCCTTTATAA TGAGAAAGAT 1260 GTTAGAGCCA GGATGAAGAG AGGCTATGAC AACCCCAACT TCATCTTGTC AGAAGTCAAT 1320 GAAACAGATG ACACCAAAAT GTAACAGTGG CTTTTCAACA GGAGTAAAGC AAAGTCTCTA 1380 AAGCTCCTAG TACCTAGAAG CATTATGAAG CAGTCAACAA TTTAGGGGTA CGAAAGTAGG 1440 ATGAGAGCCT TCAAAGTCTA CCAGCACAAA GACCCCTGAG CCCCGCAATT GTGATCCCAC 1500 AAGACATGCA TCTCCACAAG GCTACTGTAT TAGAACGTGC AATGCATTTA TATGAAACTG 1560 GTGTATGGAA GACATAGGTG CTCTCTTGAA ATCTTAAATA TGATTATTTG AGCTCATATA 1620 AGGTGGATTG GAGCAGATAA AATTATCAAA AGTTTCATGA ACAGGCCCCC G 1671 (2) INFORMATION FOR SEQ ID N0:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1703 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (Vii) IMMEDIATE SOURCE: (A) LIBRARY: Human Kidney cDNA (B) CLONE: K11P (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: TGGTTGCTTT CTTGGAGACC AAGAAAATGA GTTTTTGTTT CTACATTTAC TCCAGCAATC 60 CATGAGGTTT CTTCTCTACT GTGCCTTCAT CCCCATCCTG GGCCCTGACA AAGACAGTGT 120 GACAAGTTCT GAGCCCCACA GGTGGAATCC CAAACCAAGC AGCTCTTGCT GGTCACCCCA 180 AGATCTACTT ATACATGAAG TTTTGAAAAT CATCTCCTGA ACCTCTTCTG ACAGAGATCA 240 GGGTGTTGAC AGAAAGTATG TTCAAACATC TTCAGAAATG GGTCGTCACT CGCTTTTTTG 300 GGCATTCTCG GCAAAGAGCA AGGCTAGTCT CCAAAGATGG AAGGTGCAAC ATAGAATTTG 360 GCAATGTGGA GGCACAGTCA AGGTTTATAT TCTTTGTGGA CATCTGGACA ACGGTACTTG 420 ACCTCAAGTG GAGATACAAA ATGACCATTT TCATCACAGC CTTCTTGGGG AGTTGGTTTT 480 TCTTTGGTCT CCTGTGGTAT GCAGTAGCGT ACATTCACAA AGACCTCCCG GAATTCCATC 540 CTTCTGCCAA TCACACTCCC TGTGTGGAGA ATATTAATGG CTTGACCTCA GCTTTTCTGT 600 TTTCTCTGGA GACTCAAGTG ACCATTGGAT ATGGATTCAG GTGTGTGACA GAACAGTGTG 660 CCACTGCCAT TTTTCTGCTT ATCTTTCAGT CTATACTTGG AGTTATAATC AATTCTTTCA 720 TGTGTGGGGC CATCTTAGCC AAGATCTCCA GGCCCAAAAA ACGTGCCAAG ACCATTACGT 780 TCAGCAAGAA CGCAGTGATC AGCAAACGGG GAGGGAAGCT TTGCCTCCTA ATCCGAGTGG 840 CTAATCTCAG GAAGAGCCTT CTTATTGGCA GTCACATTTA TGGAAAGCTT CTGAAGACCA 900 CAGTCACTCC TGAAGGAGAG ACCATTATTT TGGACCAGAT CAATATCAAC TTTGTAGTTG 960 ACGCTGGGAA TGAAAATTTA TTCTTCATCT CCCCATTGAC AATTTACCAT GTCATTGATC 1020 ACAACAGCCC TTTCTTCCAC ATGGCAGCGG AGACCCTTCT CCAGCAGGAC TTTGAATTAG 1080 TGGTGTTTTT AGATGGCACA GTGGAGTCCA CCAGTGCTAC CTGCCAAGTC CGGACATCCT 1140 ATGTCCCAGA GGAGGTGCTT TGGGGCTACC GTTTTGCTCC CATAGTATCC AAGACAAAGG 1200 AAGGGAAATA CCGAGTGGAT TTCCATAACT TTAGCAAGAC AGTGGAAGTG GAGACCCCTC 1260 ACTGTGCCAT GTGCCTTTAT AATGAGAAAG ATGTTAGAGC CAGGATGAAG AGAGGCTATG 1320 ACAACCCCAA CTTCATCTTG TCAGAAGTCA ATGAAACAGA TGACACCAAA ATGTAACAGT 1380 GGCTTTTCAA CAGGAGTAAA GCAAAGTCTC TAAAGCTCCT AGTACCTAGA AGCATTATGA 1440 AGCAGTCAAC AATTTAGGGG TACGAAAGTA GGATGAGAGC CTTCAAAGTC TACCAGCACA 1500 AAGACCCCTG AGCCCCGCAA TTGTGATCCC ACAAGACATG CATCTCCACA AGGCTACTGT 1560 ATTAGAACGT GCAATGCATT TATATGAAAC TGGTGTATGG AAGACATAGG TGCTCTCTTG 1620 AAATCTTAAA TATGATTATT TGAGCTCATA TAAGGTGGAT TGGAGCAGAT AAAATTATCA 1680 AAAGTTTCAT GAACAGGCCC CCG 1703 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1591 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (vii) IMMEDIATE SOURCE: (A) LIBRARY: Human Kidney cDNA (B) CLONE: K8 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: ACCAGCACCA CTTCCTTGCT TTTTCCAGCC ATGAATGCTT CCAGTCGGAA TGTGTTTGAC 60 ACGTTGATCA GGGTGTTGAC AGAAAGTATG TTCAAACATC TTCGGAAATG GGTCGTCACT 120 CGCTTTTTTG GGCATTCTCG GCAAAGAGCA AGGCTAGTCT CCAAAGATGG AAGGTGCAAC 180 ATAGAATTTG GCAATGTGGA GGCACAGTCA AGGTTTATAT TCTTTGTGGA CATCTGGACA 240 ACGGTACTTG ACCTCAAGTG GAGATACAAA ATGACCATTT TCATCACAGC CTTCTTGGGG 300 AGTTGGTTTT TCTTTGGTCT CCTGTGGTAT GCAGTAGCGT ACATTCACAA AGACCTCCCG 360 GAATTCCATC CTTCTGCCAA TCACACTCCC TGTGTGGAGA ATATTAATGG CTTGACCTCA 420 GCTTTTCTGT TTTCTCTGGA GACTCAAGTG ACCATTGGAT ATGGATTCAG GTGTGTGACA 480 GAACAGTGTG CCACTGCCAT TTTTCTGCTT ATCTTTCAGT CTATACTTGG AGTTATAATC 540 AATTCTTTCA TGTGTGGGGC CATCTTAGCC AAGATCTCCA GGCCCAAAAA ACGTGCCAAG 600 ACCATTACGT TCAGCAAGAA CGCAGTGATC AGCAAACGGG GAGGGAAGCT TTGCCTCCTA 660 ATCCGAGTGG CTAATCTCAG GAAGAGCCTT CTTATTGGCA GTCACATTTA TGGAAAGCTT 720 CTGAAGACCA CAGTCACTCC TGAAGGAGAG ACCATTATTT TGGACCAGAT CAATATCAAC 780 TTTGTAGTTG ACGCTGGGAA TGAAAATTTA TTCTTCATCT CCCCATTGAC AATTTACCAT 840 GTCATTGATC ACAACAGCCC TTTCTTCCAC ATGGCAβCGG AGACCCTTCT CCAGCAGGAC 900 TTTGAATTAG TGGTGTTTTT AGATGGCACA GTGGAGTCCA CCAGTGCTAC CTGCCAAGTC 960 CGGACATCCT ATGTCCCAGA GGAGGTGCTT TGGGGCTACC GTTTTGCTCC CATAGTATCC 1020 AAGACAAAGG AAGGGAAATA CCGAGTGGAT TTCCATAACT TTAGCAAGAC AGTGGAAGTG 1080 GAGACCCCTC ACTGTGCCAT GTGCCTTTAT AATGAGAAAG ATGTTAGAGC CAGGATGAAG 1140 AGAGGCTATG ACAACCCCAA CTTCATCTTG TCAGAAGTCA ATGAAACAGA TGACACCAAA 1200 ATGTAACAGT GGCTTTTCAA CGGGAGTAAA GCAAAGTCTC TAAAGCTCCT AGTACCTAGA 1260 AGCATTATGA AGCAGTCAAC AATTTAGGGG TACGAAAGTA GGATGAGAGC CTTCAAAGTC 1320 TACCAGCACA AAGACCCCTG AGCCCCGCAA TTGTGATCCC ACAAGACATG CATCTCCACA 1380 AGGCTACTGT ATTAGAACGT GCAATGCATT TATATGAAAC TGGTGTATGG AAGACATAGG 1440 TGCTCTCTTG AAATCTTAAA TATGATTATT TGAGCTCATA TAAGGTGGAT TGGAGCAGAT 1500 AAAATTATCA AAAGTTTCAT GAACAGGCCA AACAAAATAT TTTTTAAAGT TTCCTTAAAG 1560 AAGTTATGAA CTTTAGAAAG GATCAGGGCC G 1591

Claims: CLAIMS What is claimed is: 1. An isolated DNA molecule encoding a human kidney potassium channel protein having the sequences shown in Figures 1, 2, 3, 4, or 5; from the clones named K-8, K-ll or K-12, or derivatives selected from obvious variations thereof, or having the DNA coding for the N- terminal protein sequences as shown in Table 1; from the clones named K-2, K-6, K-8, K-l l, or K-26 and having the remaining DNA not shown in Table 1 but as shown in Figures 1-5, or having the DNA coding any of about the first 26 N terminal amino acids, including any deletions, of the protein coded for by the DNA shown in Figures 1-5, or the protein shown in Figure 6 or Table 1, or a DNA molecule 90 percent homologous to any of the above described DNA molecules thereof. 2. An isolated DNA molecule, of claim 1, encoding a human kidney potassium channel of claim 1, having the sequence shown in Figure 1, describing the clone K26, or about that of Figure 1, or an obvious variation from Figure 1, or a 90 percent homologous DNA molecule thereof. 3. An isolated DNA molecule, of claim 1, encoding a human kidney potassium channel of claim 1, having the sequence shown in Figure 2, describing the clone K26-plus, or about that of Figure 2 or an obvious variation from Figure 2 or a 90 percent homologous DNA molecule thereof. 4. An isolated DNA molecule, of claim 1, encoding a human kidney potassium channel of claim 1, having the sequence shown in Figure 3, describing the clone Kll, or about that of Figure 3, or an obvious variation from Figure 3, or a 90 percent homologous DNA molecule thereof. 5. An isolated DNA molecule, of claim 1, encoding a human kidney potassium channel of claim 1, having the sequence shown in Figure 4, describing the clone Kll -plus, or about that of Figure 4, or an obvious variation from the DNA shown in Figure 4, or a 90 percent homologous DNA molecule thereof. 6. An isolated DNA molecule, of claim 1, encoding a human kidney potassium channel of claim 1, having the sequence shown in Figure 5, describing the clone K-8, or about that of Figure 5, or an obvious variation from Figure 5, or homologous DNA thereof. 7. An isolated DNA molecule, of claim 1, encoding a human kidney potassium channel of claim 1, having the protein sequence shown in Table 1, describing the clone K-2, or about that of the sequence shown in Table 1, or an obvious variation from the DNA that encodes for the protein sequence of K-2 shown in Table 1, or a 90 percent homologous DNA molecule to that sequence, and having a remaining sequence 90 percent homologous to the sequences shown in Figures 1-6 and beginning with the sequence starting 20 amino acids from the N-terminal sequence of ROM-Kl or K8, that is, from the protein sequence MFKHLR etc. 8. An isolated DNA molecule, of claim 1, encoding a human kidney potassium channel of claim 1, having the protein sequence shown in Table 1, describing the clone K-6, or about that of the sequence shown in Table 1, or an obvious variation from the DNA that encodes for the protein sequence of K-2 shown in Table 1, or a 90 percent homologous DNA molecule to that sequence, and having a remaining sequence 90 percent homologous to the sequences shown in Figures 1-6 and beginning with the sequence starting 20 amino acids from the N-terminal sequence of ROM-Kl or K8, that is with the sequence MFKHLR etc. 9. A vector comprising a DNA molecule described in claim 1. 10. A plasmid comprising a DNA molecule described in claim 1. 11. A vector of claim 9 adapted for expression in a bacterial cell. 12. A vector of claim 9 adapted for expression in a mammalian cell. 13. A vector of claim 9 adapted for expression in a yeast cell. 14. A plasmid of claim 10 adapted for expression in a bacterial cell. 15. A plasmid of claim 10 adapted for expression in a mammalian cell. 16. A plasmid of claim 10 adapted for expression in a yeast cell. 17. A bacterial cell comprising the plasmid of claim 14. 18. An isolated mammalian cell comprising the plasmid of claim 15. 19. A yeast cell comprising the plasmid of claim 16. 20. The method of using the bacterial cell of claim 17 to screen for compounds that modulate human kidney potassium channel activity. 21. The method of using the isolated mammalian cell of claim 18 to screen for compounds that modulate human kidney potassium channel activity. 22. The method of claim 21, comprising the following steps: a) growing cells expressing a cloned K + channel to confluence, b) equilibrating the cells of a) with a balanced salt solution, c) making baseline measurements of the equilibrated cells, d) adding one test compound or a cocktail of test compounds to the cells and recording changes in membrane potential, e) testing compounds that depolarize cells expressing the K + on wild type or mock transfected controls to establish selectivity, f) selecting the compoimds that are shown to selectively block K + . 23. The method of claim 21 comprising the following steps: a) growing cells expressing the cloned K8, Kll, K26 or related K + channel to confluence in a 96 well microtest plate, b) equilibrating the cells of a) with a balanced salt solution, such as with 5 μM DiBAC 4 (3) in Earle's balanced salt solution containing 20 mM HEPES, c) making baseline measurements of the equilibrated cells, d) adding one test compound or a cocktail of test compounds to the cells and recording changes in membrane potential, e) testing compounds that depolarize cells expressing the K + on wild type or mock transfected controls to establish selectivity, f) selecting the compoimds that are shown to selectively block K + . 24. The method of using the yeast cell of claim 19 to screen for compounds that modulate human kidney potassium channel activity. 25. An isolated protein functioning in a mammalian cell, as a human kidney potassium channel protein having the sequences shown in Figures 1, 2, 3, 4, or 5; from the clones named K-8, K-l l or K-12, or derivatives selected from obvious variations thereof, or having protein from the the N-terminal protein sequences as shown in Table 1; from the clones named K-2, K- 6, K-8, K-ll, or K-26 and having the remaining DNA not shown in Table 1 but as shown in Figures 1-5, or having the DNA coding any of about the first 26 N terminal amino acids of the protein coded for, by the DNA shown in Figures 1-5, or the protein shown in Figure 6 or Table 1, or by the protein from a DNA molecule 90 percent homologous to any of the above described DNA molecules thereof. 26. A isolated protein of claim 25, functioning in a mammalian cell, as a human kidney potassium channel protein having the sequences shown in Figures 1, 2, 3, 4, 5; from the clones named K-8, K-ll or K-12, or derivatives selected from obvious variations thereof, or from 90 percent homologous sequences thereof. 27. A isolated protein of claim 25, functioning in a mammalian cell, having the terminal protein sequence for the N-terminal protein sequences as shown in Table 1; from the clones named K-2, K-6, and having the remaining DNA not shown in Table 1 but as shown in Figures 1-5, 28. A protein of claim 25, functioning in a mammalian cell, having the terminal protein sequence for the N-terminal protein sequences of any of about the first 26 N terminal amino acids of the protein coded for by the DNA shown in Figures 1-5, including any deletions, or the proteins shown in Figure 6, or a DNA molecule 90 percent homologous to any of the above described DNA molecules thereof.

Inventors: BIENKOWSKI MICHAEL JEROME, GROPPI VINCENT EDWARD JR, BIENKOWSKI, MICHAEL, JEROME, GROPPI, VINCENT, EDWARD, JR.
Applicants: BIENKOWSKI MICHAEL JEROME, GROPPI VINCENT EDWARD JR, UPJOHN CO, BIENKOWSKI, MICHAEL, JEROME, GROPPI, VINCENT, EDWARD, JR., THE UPJOHN COMPANY
Application year: 1994
Main classification: C12N15
IPC codes: C07K14, C12N1, C12N5, C12N15, C12P21, C12R1